1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Small Molecule Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy Drugs
1.2.3 Immunomodulating Drugs
1.2.4 Targeted Therapy Drugs
1.2.5 Hormonal Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Small Molecule Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Lung Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncology Small Molecule Drugs Market Perspective (2017-2028)
2.2 Oncology Small Molecule Drugs Growth Trends by Region
2.2.1 Oncology Small Molecule Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Oncology Small Molecule Drugs Historic Market Size by Region (2017-2022)
2.2.3 Oncology Small Molecule Drugs Forecasted Market Size by Region (2023-2028)
2.3 Oncology Small Molecule Drugs Market Dynamics
2.3.1 Oncology Small Molecule Drugs Industry Trends
2.3.2 Oncology Small Molecule Drugs Market Drivers
2.3.3 Oncology Small Molecule Drugs Market Challenges
2.3.4 Oncology Small Molecule Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Small Molecule Drugs Players by Revenue
3.1.1 Global Top Oncology Small Molecule Drugs Players by Revenue (2017-2022)
3.1.2 Global Oncology Small Molecule Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Oncology Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Small Molecule Drugs Revenue
3.4 Global Oncology Small Molecule Drugs Market Concentration Ratio
3.4.1 Global Oncology Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Small Molecule Drugs Revenue in 2021
3.5 Oncology Small Molecule Drugs Key Players Head office and Area Served
3.6 Key Players Oncology Small Molecule Drugs Product Solution and Service
3.7 Date of Enter into Oncology Small Molecule Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Small Molecule Drugs Breakdown Data by Type
4.1 Global Oncology Small Molecule Drugs Historic Market Size by Type (2017-2022)
4.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2023-2028)
5 Oncology Small Molecule Drugs Breakdown Data by Application
5.1 Global Oncology Small Molecule Drugs Historic Market Size by Application (2017-2022)
5.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Oncology Small Molecule Drugs Market Size (2017-2028)
6.2 North America Oncology Small Molecule Drugs Market Size by Country (2017-2022)
6.3 North America Oncology Small Molecule Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Oncology Small Molecule Drugs Market Size (2017-2028)
7.2 Europe Oncology Small Molecule Drugs Market Size by Country (2017-2022)
7.3 Europe Oncology Small Molecule Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Small Molecule Drugs Market Size (2017-2028)
8.2 Asia-Pacific Oncology Small Molecule Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Oncology Small Molecule Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Oncology Small Molecule Drugs Market Size (2017-2028)
9.2 Latin America Oncology Small Molecule Drugs Market Size by Country (2017-2022)
9.3 Latin America Oncology Small Molecule Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Small Molecule Drugs Market Size (2017-2028)
10.2 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Small Molecule Drugs Introduction
11.1.4 Roche Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Oncology Small Molecule Drugs Introduction
11.2.4 Novartis Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Oncology Small Molecule Drugs Introduction
11.3.4 Pfizer Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.3.5 Pfizer Recent Development
11.4 Celgene
11.4.1 Celgene Company Detail
11.4.2 Celgene Business Overview
11.4.3 Celgene Oncology Small Molecule Drugs Introduction
11.4.4 Celgene Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.4.5 Celgene Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Oncology Small Molecule Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Oncology Small Molecule Drugs Introduction
11.6.4 Amgen Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Oncology Small Molecule Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.7.5 Johnson & Johnson Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Oncology Small Molecule Drugs Introduction
11.8.4 AbbVie Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.8.5 AbbVie Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Oncology Small Molecule Drugs Introduction
11.9.4 Sanofi Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.9.5 Sanofi Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Oncology Small Molecule Drugs Introduction
11.10.4 Takeda Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.10.5 Takeda Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Oncology Small Molecule Drugs Introduction
11.11.4 Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.11.5 Eli Lilly Recent Development
11.12 Bayer
11.12.1 Bayer Company Detail
11.12.2 Bayer Business Overview
11.12.3 Bayer Oncology Small Molecule Drugs Introduction
11.12.4 Bayer Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.12.5 Bayer Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Oncology Small Molecule Drugs Introduction
11.13.4 AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.13.5 AstraZeneca Recent Development
11.14 Astellas
11.14.1 Astellas Company Detail
11.14.2 Astellas Business Overview
11.14.3 Astellas Oncology Small Molecule Drugs Introduction
11.14.4 Astellas Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.14.5 Astellas Recent Development
11.15 Merck
11.15.1 Merck Company Detail
11.15.2 Merck Business Overview
11.15.3 Merck Oncology Small Molecule Drugs Introduction
11.15.4 Merck Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.15.5 Merck Recent Development
11.16 Biogen Idec
11.16.1 Biogen Idec Company Detail
11.16.2 Biogen Idec Business Overview
11.16.3 Biogen Idec Oncology Small Molecule Drugs Introduction
11.16.4 Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.16.5 Biogen Idec Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Oncology Small Molecule Drugs Introduction
11.17.4 Eisai Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.17.5 Eisai Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Small Molecule Drugs Introduction
11.18.4 Teva Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Small Molecule Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.19.5 Otsuka Recent Development
11.20 Ipsen
11.20.1 Ipsen Company Detail
11.20.2 Ipsen Business Overview
11.20.3 Ipsen Oncology Small Molecule Drugs Introduction
11.20.4 Ipsen Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.20.5 Ipsen Recent Development
11.21 Gilead Sciences
11.21.1 Gilead Sciences Company Detail
11.21.2 Gilead Sciences Business Overview
11.21.3 Gilead Sciences Oncology Small Molecule Drugs Introduction
11.21.4 Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.21.5 Gilead Sciences Recent Development
11.22 Exelixis
11.22.1 Exelixis Company Detail
11.22.2 Exelixis Business Overview
11.22.3 Exelixis Oncology Small Molecule Drugs Introduction
11.22.4 Exelixis Revenue in Oncology Small Molecule Drugs Business (2017-2022)
11.22.5 Exelixis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
